Active Filter(s):
Details:
PAQ's novel autophagosome-tethering compounds (ATTECs) are small molecules with the potential to selectively catalyze autophagy-dependent degradation of a wide range of disease-causing substrates.
Lead Product(s): Autophagosome-tethering Compound Based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Sherpa Healthcare
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 15, 2021